APLS - Apellis Pharmaceuticals, Inc.

QQQ $ 619.53 $ -3.74 (-0.6 %)

DIA $ 482.77 $ 2.24 (0.47 %)

SPY $ 681.90 $ -1.55 (-0.23 %)

TLT $ 90.02 $ 0.16 (0.18 %)

GLD $ 387.00 $ 5.86 (1.54 %)

Previous Close

$ 20.02

Open

$ 19.42

Bid

$ 18.82 x 5

Ask

$ 20.81 x 9

Day's Range

-- - --

52 Week Range

$ 16.10 - $ 35.72

Volume

1,811,500

Average Volume

Market Cap

2.53B

Beta (5Y Monthly)

$ 0.80

PE Ratio (TTM)

$ 56.31

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	10-30-2025	09-30-2025	10-Q
2	07-31-2025	06-30-2025	10-Q
3	05-07-2025	03-31-2025	10-Q
4	02-28-2025	01-01-1970	10-K
5	11-05-2024	09-30-2024	10-Q
6	08-01-2024	06-30-2024	10-Q
7	05-07-2024	03-31-2024	10-Q
8	02-27-2024	12-31-2023	10-K
9	11-01-2023	09-30-2023	10-Q
10	07-31-2023	06-30-2023	10-Q
11	05-04-2023	03-31-2023	10-Q
12	02-21-2023	12-31-2022	10-K
13	11-07-2022	09-30-2022	10-Q
14	08-08-2022	06-30-2022	10-Q
15	05-04-2022	03-31-2022	10-Q
16	02-28-2022	12-31-2021	10-K
17	11-08-2021	09-30-2021	10-Q
18	08-09-2021	06-30-2021	10-Q
19	04-28-2021	03-31-2021	10-Q
20	02-25-2021	12-31-2020	10-K
21	11-02-2020	09-30-2020	10-Q
22	07-30-2020	06-30-2020	10-Q
23	04-29-2020	03-31-2020	10-Q
24	02-27-2020	12-31-2019	10-K
25	11-05-2019	09-30-2019	10-Q
26	07-31-2019	06-30-2019	10-Q
27	05-07-2019	03-31-2019	10-Q
28	02-26-2019	12-31-2018	10-K
29	11-13-2018	09-30-2018	10-Q
30	07-31-2018	06-30-2018	10-Q
31	04-30-2018	03-31-2018	10-Q
32	03-19-2018	12-31-2017	10-K
33	12-20-2017	09-30-2017	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

this-undervalued-biotech-might-have-just-proven-its-star-drugs-staying-power

This Undervalued Biotech Might Have Just P...
11/12/2025 18:36:29

Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and ana...

Apellis Pharmaceuticals Data From GALE Ext...
11/12/2025 12:15:38

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study followin...

this-brinker-international-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday

This Brinker International Analyst Begins ...
11/06/2025 13:34:52

Wolfe Research Initiates Coverage On Apell...
11/06/2025 13:25:45

Wolfe Research analyst Andy Chen initiates coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a Peer Perform rating.

JP Morgan Maintains Overweight on Apellis ...
11/05/2025 19:49:08

JP Morgan analyst Anupam Rama maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and lowers the price target ...

Mizuho Maintains Neutral on Apellis Pharma...
11/03/2025 17:57:55

Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and lowers the price target ...

Citigroup Maintains Buy on Apellis Pharmac...
10/31/2025 20:24:46

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target f...

TD Cowen Maintains Buy on Apellis Pharmace...
10/31/2025 18:01:01

TD Cowen analyst Phil Nadeau maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $50...

Baird Maintains Outperform on Apellis Phar...
10/31/2025 12:24:53

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and raises the price target fro...

HC Wainwright & Co. Maintains Buy on Apell...
10/31/2025 10:22:22

HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price...

12 Health Care Stocks Moving In Thursday's...
10/30/2025 17:07:10

Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

Apellis Pharmaceuticals Q3 EPS $1.67 Beats...
10/30/2025 11:06:49

Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly earnings of $1.67 per share which beat the analyst consensus estimate ...

Insights Ahead: Apellis Pharmaceuticals's ...
10/29/2025 20:01:07

Apellis Highlights New Phase 3 Data Showin...
10/20/2025 11:13:52

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced new data from the open-label period of the Phase 3 VALIANT study th...

Expert Outlook: Apellis Pharmaceuticals Th...
10/15/2025 22:01:52

Wells Fargo Upgrades Apellis Pharmaceutica...
10/15/2025 12:44:12

Wells Fargo analyst Derek Archila upgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Equal-Weight to Overweight and raises ...

12 Analysts Assess Apellis Pharmaceuticals...
09/26/2025 18:00:49

During the last three months, 12 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ: APLS), revealing diverse...

Goldman Sachs Downgrades Apellis Pharmaceu...
09/26/2025 16:51:18

Goldman Sachs analyst Salveen Richter downgrades Apellis Pharmaceuticals (NASDAQ: APLS) from Neutral to Sell and lowers the ...

concentrix-posts-downbeat-earnings-joins-legacy-education-kingsoft-cloud-and-other-big-stocks-moving-lower-in-fridays-pre-market-session

Concentrix Posts Downbeat Earnings, Joins ...
09/26/2025 12:04:21

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.